phrykt

Axsome Therapeutics, Inc. (AXSM): who owns it and who trades it

As of Nov 16, 2026, AXSM insiders reported 30 open-market sales worth $113M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Herriot Tabuteau (CEO), with $76M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Axsome Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AXSM

503 funds and institutions reported AXSM shares worth $9.5B at the end of Q2 2026, about 75% of the company. The largest holder is BlackRock, Inc. with 6.0%.

Funds and institutions (13F) 75%Everyone else 25%

10 largest owners, by share of the company

BlackRock, Inc.6.0%
Vanguard Portfolio Management LLC3.9%
Vanguard Capital Management LLC3.8%
Invesco Ltd.3.2%
FMR LLC (Fidelity)3.0%
Geode Capital Management, LLC1.9%
Assenagon Asset Management S.A.1.8%
Morgan Stanley1.6%
State Street Corp1.5%
Deep Track Capital, LP1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.3.10M6.03%$760M-21%
Vanguard Portfolio Management LLC1.98M3.85%$486M-4%
Vanguard Capital Management LLC1.97M3.82%$481M+1%
Invesco Ltd.1.67M3.25%$409M+29%
FMR LLC (Fidelity)1.54M2.99%$377M-2%
Geode Capital Management, LLC967,1721.88%$237M-17%
Assenagon Asset Management S.A.909,3641.77%$223M+5%
Morgan Stanley804,0821.56%$197M+69%
State Street Corp785,6611.53%$192M-20%
Deep Track Capital, LP700,0001.36%$171M-36%
Two Sigma Investments, LP669,4781.30%$164M+107%
Franklin Resources Inc668,3731.30%$164M+52%
Wellington Management Group LLP653,9201.27%$160M-43%
Alethea Capital Management, LLC648,7561.26%$159M-0%
T. Rowe Price Associates642,8931.25%$157M-51%
D. E. Shaw & Co., Inc.604,7531.18%$148M+0%
Millennium Management LLC556,0881.08%$136M–
Nomura Asset Management International Inc.539,4071.05%$132M-34%
Norges Bank514,2661.00%$126M–
First Trust Advisors LP482,0610.94%$118M-17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AXSM insiders reported $0 of open-market purchases and $113M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$113M
30 trades, 8 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 3, 2026
Filed Sep 3, 2026

Purchases and sales by month

$27.5M$27.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 3, 2026Mark L. JacobsonChief Operating OfficerSale10,000$208.65$2.1MForm 4
Aug 6, 2026Herriot TabuteauCEOSale4,660$213.95$997KForm 4
Aug 5, 2026Herriot TabuteauCEOSale45,004$212.01$9.5MForm 4
Jul 1, 2026Herriot TabuteauCEOSale49,666$240.25$11.9MForm 4
Jun 11, 2026Roger JeffsDirectorSale286$249.12$71.2KForm 4
Jun 10, 2026Roger JeffsDirectorSale286$246.18$70.4KForm 4
Jun 10, 2026Susan MahonyDirectorSale300$246.18$73.9KForm 4
Jun 10, 2026Mark ColemanDirectorSale643$249.00$160KForm 4
Jun 9, 2026Susan MahonyDirectorSale300$237.21$71.2KForm 4
Jun 9, 2026Herriot TabuteauCEOSale49,670$241.01$12MForm 4
Jun 9, 2026Nick PizzieCFOSale33,000$240.09$7.9MForm 4
Jun 2, 2026Mark ColemanDirectorSale5,537$223.39$1.2MForm 4
Jun 1, 2026Mark ColemanDirectorSale6,000$230.30$1.4MForm 4
May 29, 2026Mark ColemanDirectorSale6,000$233.46$1.4MForm 4
May 5, 2026Mark L. JacobsonChief Operating OfficerSale233$228.18$53.2KForm 4
May 4, 2026Mark L. JacobsonChief Operating OfficerSale4,517$227.94$1MForm 4
Apr 22, 2026Ari MaizelChief Commercial OfficerSale7,500$182.42$1.4MForm 4
Feb 26, 2026Mark ColemanDirectorSale25,000$161.11$4MForm 4
Feb 26, 2026Mark L. JacobsonChief Operating OfficerSale35,378$161.88$5.7MForm 4
Feb 2, 2026Herriot TabuteauCEOSale32,410$185.60$6MForm 4
Jan 22, 2026Nick PizzieCFOSale12,000$187.92$2.3MForm 4
Jan 21, 2026Ari MaizelChief Commercial OfficerSale7,500$184.44$1.4MForm 4
Jan 7, 2026Herriot TabuteauCEOSale31,261$170.38$5.3MForm 4
Jan 6, 2026Herriot TabuteauCEOSale29,450$172.33$5.1MForm 4
Jan 5, 2026Herriot TabuteauCEOSale78,703$171.28$13.5MForm 4
Dec 31, 2025Mark E SaadDirectorSale6,231$165.18$1MForm 4
Dec 31, 2025Mark E SaadDirectorSale31,346$165.18$5.2MForm 4
Dec 4, 2025Herriot TabuteauCEOSale10,558$148.18$1.6MForm 4
Dec 3, 2025Herriot TabuteauCEOSale20,163$146.94$3MForm 4
Dec 2, 2025Herriot TabuteauCEOSale49,252$144.59$7.1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Herriot TabuteauChief Executive Officer, Director, 10% owner–$76MAug 6, 2026
Nick PizzieChief Financial Officer–$10.2MJun 9, 2026
Mark L. JacobsonChief Operating Officer–$8.9MSep 3, 2026
Mark ColemanDirector–$8.2MJun 10, 2026
Mark E SaadDirector–$6.2MDec 31, 2025
Ari MaizelChief Commercial Officer–$2.8MApr 22, 2026
Susan MahonyDirector–$145KJun 10, 2026
Roger JeffsDirector–$142KJun 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AXSM short interest

Moderate short interest. 6.2% of AXSM shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 18%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.26M AXSM shares were sold short, 6.2% of the shares outstanding, up 4.9% from the report before. At the average daily volume of 975,189 shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

6.20%May 15Oct 306.85%

Days to cover

3.4May 15Oct 306.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.26M6.20%+5%975,1893.4
Oct 15, 20263.11M5.94%-6%932,4953.3
Sep 30, 20263.31M6.31%+5%758,3604.4
Sep 15, 20263.14M5.99%+2%605,1635.2
Aug 31, 20263.08M5.88%-4%528,0025.8
Aug 14, 20263.21M6.12%-6%804,5374.0
Jul 31, 20263.41M6.62%+13%666,5365.1
Jul 15, 20263.02M5.88%+15%800,5683.8
Jun 30, 20262.63M5.12%-20%1.64M1.6
Jun 15, 20263.28M6.38%+6%684,1094.8
May 29, 20263.09M6.01%+11%619,2965.0
May 15, 20262.78M5.40%+1%946,3112.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Axsome Therapeutics company events

Axsome Therapeutics filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026AnnouncementThe Company updated its corporate presentation and posted such corporate presentation to the Company’s website. Filing
  2. Aug 10, 2026AnnouncementThe Company updated its corporate presentation and posted such corporate presentation to the Company’s website. Filing
  3. Jul 15, 2026AnnouncementAxsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. Filing
  4. Jun 9, 2026LeadershipThe Compensation Committee of the Board of Directors of Axsome Therapeutics, Inc. approved the adoption of the Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan, effective on June 5, 2026, which provides for severance benefits to certain key employees, including the Company’s… Filing
  5. Jun 9, 2026VoteReported shareholder vote results. Filing
  6. Jun 3, 2026AnnouncementAxsome Therapeutics, Inc. issued a press release entitled “Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation.” The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. Filing
  7. May 4, 2026AnnouncementThe Company updated its corporate presentation and posted such corporate presentation to the Company’s website. Filing
  8. Apr 30, 2026AnnouncementAxsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY ® for the treatment of agitation associated with dementia due to Alzheimer’s disease. Filing
  9. Apr 1, 2026AnnouncementAxsome Therapeutics, Inc. issued a press release entitled “Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and other Neuropsychiatric Conditions.” For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit… Filing
  10. Feb 23, 2026ResultsReleased financial results. Filing
  11. Feb 17, 2026AnnouncementAxsome Therapeutics, Inc. issued a press release announcing that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI ® (solriamfetol). Filing
  12. Jan 12, 2026AnnouncementAs reported above, on January 12, 2026, the Company issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit 99.1 hereto and is… Filing
  13. Dec 31, 2025AnnouncementAxsome Therapeutics, Inc. issued a press release announcing the U.S. Food and Drug Administration’s acceptance and grant of Priority Review for its supplemental New Drug Application for the treatment of Alzheimer’s Disease Agitation. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Axsome Therapeutics financials

Famous investors that hold AXSM

5 of the 50 well-known investors we track reported holding AXSM in their latest 13F filing. The largest position is Israel Englander's, worth $244M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.32M$244M0.2%+138%
Jim Simons · Renaissance TechnologiesQ3 2026205,800$37.9M0.1%-21%
Steve Cohen · Point72 Asset ManagementQ3 2026154,274$28.4M0.0%-63%
Ray Dalio · Bridgewater AssociatesQ3 2026125,808$23.2M0.1%+116%
Ken Griffin · Citadel AdvisorsQ3 202619,864$3.7M0.0%-92%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Axsome Therapeutics, Inc. (AXSM) stock

Who owns the most AXSM stock?

The largest reported owner of Axsome Therapeutics, Inc. (AXSM) is BlackRock, Inc., with 6.0% of the company. In total, 503 funds and institutions reported holding AXSM at the end of Q2 2026, together about 75% of the shares. See the largest owners.

Are AXSM insiders buying or selling?

In the last 12 months, AXSM insiders reported no open-market purchases and 30 sales worth $113M. The latest trade was on Sep 3, 2026. See every trade.

What is the short interest in AXSM?

As of Oct 30, 2026, 3.26M AXSM shares were sold short, 6.2% of the shares outstanding, up 4.9% from the report before. At the average daily volume of 975,189 shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Which famous investors hold AXSM?

5 of the 50 well-known investors we track reported AXSM in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $244M. See all holders.

Executive pay

Axsome Therapeutics's chief executive was paid a total of $10.3M for the year ended Dec 31, 2025, down 1% from $10.4M the year before. In the last 12 months, Axsome Therapeutics's executives and directors bought no stock on the open market and sold $113M.

Chief executive, total pay$10.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$33.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.